VolitionRx announced a 300% revenue increase in Q1 2026, reaching $1 million, driven by progress in their Capture-Seq™ cancer detection platform and Nu.Q® veterinary cancer tests. The company submitted a clinical manuscript for a feline lymphoma test, expecting a $5 million milestone payment, and is engaged in licensing talks with over a dozen global diagnostic firms. Their technology shows over 95% sensitivity for early-stage cancers and is expanding into sepsis detection with a finger-prick test. VolitionRx aims to secure licensing deals to commercialize their multi-billion dollar market opportunities, with routine clinical use in lung cancer expected in France by end of 2026.
JenaValve Technology, Inc. has appointed Edward Sarnowski as Chief Technology Officer to lead its research and development efforts. This move follows the recent FDA approval of JenaValve's Trilogy Transcatheter Heart Valve System, designed to treat s...
AsymBio, a biologics CDMO, introduced its Conjugation Toolbox to support customized and scalable process development for next-generation bioconjugates like antibody-drug conjugates (ADCs). This platform offers flexible conjugation methods, including ...
Paramount Skydance's proposed $110 billion acquisition of Warner Bros. Discovery is nearing potential approval from the U.S. Department of Justice (DOJ) after antitrust discussions showed early signs of support. Paramount CEO David Ellison reassured ...
Zscaler reported strong third-quarter results with revenue of $850.48 million and adjusted earnings of $1.08 per share, both surpassing analyst expectations. Annual recurring revenue grew 25% to $3.5 billion, driven by demand for its Zero Trust platf...
HUHU HUHUTECH International's German subsidiary won a $15 million contract to supply High-Purity Process systems to a leading European semiconductor foundry. The deal supports new wafer production lines in Dresden targeting premium smartphones, AI, a...
